Study
| Phase III, randomized, double-blind, placebo-controlled |
| Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma |
| Pembrolizumab + Chemotherapy (n=365) vs. Chemotherapy (n=548) |
Efficacy
| dMMR cohort |
| mPFS: NR vs. 7.6 mos, p<0.001 |
| 12 mos PFS: 74% vs. 38%, p<0.001 |
| pMMR cohort |
| mPFS: 13.1 vs. 8.7 mos, p<0.001 |
Safety
| Any grade: fatigue (71.6% vs 55.7%), peripheral sensory neuropathy (65% vs.62%), anemia (57.8% vs. 54.7%), nausea (50.5% vs. 41.5%) |
| Grade≥3 AEs: Anemia (19.3% vs. 10.4%), neutropenia (11.9% vs. 17.0%) |
N Engl J Med 2023; 27 MAR
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
http://doi.org/10.1056/NEJMoa2302312
Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023
